DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34⁺ CD15^- cells in early chronic-phase chronic myeloid leukemia.

ABSTRACT: Despite the high efficiency of tyrosine kinase inhibitors (TKI), some patients with chronic myeloid leukemia (CML) will display residual disease that can become resistant to treatment, indicating intraclonal heterogeneity in chronic-phase CML (CP-CML). To determine the basis of this heterogeneity, we conducted the first exhaustive characterization of the DNA methylation pattern of sorted CP-CML CD34⁺ CD15^- (immature) and CD34^- CD15⁺ (mature) cells at diagnosis (prior to any treatment) and compared it to that of CD34⁺ CD15^- and CD34^- CD15⁺ cells isolated from healthy donors (HD). In both cell types, we identified several hundreds of differentially methylated regions (DMRs) showing DNA methylation changes

SUBMITTER: Maupetit-Mehouas S 

PROVIDER: S-EPMC5983208 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature